Patent application number | Description | Published |
20090258915 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE - Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases. | 10-15-2009 |
20100183570 | NON-EMBRYONIC STEM CELLS AND USES THEREOF - Disclosed are novel stem cells of non-embryonic origins and the uses thereof. | 07-22-2010 |
20100215622 | TREATMENT OF IMMUNOSUPPRESSION-RELATED DISORDERS - Disclosed are methods of using blastomere-like stem cells to treat a number of immunodeficiency disorders. | 08-26-2010 |
20110245201 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 10-06-2011 |
20110245304 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE - Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases. | 10-06-2011 |
20110262920 | METHODS FOR PREDICTING SURVIVAL IN CANCER PATIENTS - A method for survival prediction in cancer patients is provided. In one embodiment, the survival prediction is determined by the presence or absence of KRAS gene region deletion and/or loss of Chromosome 12 (Ch. 12) in cancer tumor tissue. In another embodiment, the presence or absence of KRAS gene region deletion and/or loss of Ch. 12 in cancer tumor tissue is used to predict survival in non-small-cell lung cancer (NSCLC) patients. | 10-27-2011 |
20120253048 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE - Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases. | 10-04-2012 |
20130012398 | Methods for small RNA sequencing - Next generation sequencing technologies are becoming a preferred method for sequencing nucleic acids and profiling miRNAs. Experimental results disclosed herein show that the most common platform for preparing nucleic acids such as miRNAs for sequencing introduces serious biases. Provided herein are compositions and methods for improved sequencing and miRNA profiling using a set of customized ligation adaptors. | 01-10-2013 |
20130017540 | IDENTIFICATION OF MUTATION TYPES ASSOCIATED WITH ACQUIRED RESISTANCE AND METHODS FOR USING SAME - Methods for identifying or classifying a gene mutation type associated with acquired drug resistance of cancer is provided. Said methods may include determining a total copy number (N) of a susceptible gene in a cancer cell, identifying a mutant copy number of the susceptible gene, determining a mutant copy number sufficient to cause acquired drug resistance (M); and comparing N with M to identify or classify the mutation type in the cancer cell. | 01-17-2013 |
20130338103 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 12-19-2013 |